Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review

New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were publishe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tomasz Marjanski, Robert Dziedzic, Anna Kowalczyk, Witold Rzyman
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lung cancer non-small cell lung cancer surgery neoadjuvant therapy EGFR-TKIs ALK-TKIs Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/c374715028cc4681a3df8270fb6f11ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c374715028cc4681a3df8270fb6f11ae
record_format	dspace
spelling	oai:doaj.org-article:c374715028cc4681a3df8270fb6f11ae2021-11-25T17:54:39ZSafety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review10.3390/ijms2222122441422-00671661-6596https://doaj.org/article/c374715028cc4681a3df8270fb6f11ae2021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12244https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were published yet. The current narrative review proves that targeted therapies are safe in neoadjuvant approach. Unsurprisingly, administration of therapy is related to an acceptable toxicity profile. Severe adverse events’ rate that rarely compromises outcomes of patients with advanced lung cancer is not that commonly accepted in early lung cancer as it may lead to missing the chance of curative surgery. Among those complications, the most important factors that may limit the use of targeted therapies are severe respiratory adverse events precluding the resection occurring after treatment with some anaplastic lymphoma kinase and rarely after epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in the presented literature assessing the feasibility of neoadjuvant therapies with anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase inhibitors, we did not find any unexpected intraoperative events that would be of special interest to a thoracic surgeon. Moreover, the postoperative course was associated with typical rate of complications.Tomasz MarjanskiRobert DziedzicAnna KowalczykWitold RzymanMDPI AGarticlelung cancernon-small cell lung cancersurgeryneoadjuvant therapyEGFR-TKIsALK-TKIsBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12244, p 12244 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer non-small cell lung cancer surgery neoadjuvant therapy EGFR-TKIs ALK-TKIs Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	lung cancer non-small cell lung cancer surgery neoadjuvant therapy EGFR-TKIs ALK-TKIs Biology (General) QH301-705.5 Chemistry QD1-999 Tomasz Marjanski Robert Dziedzic Anna Kowalczyk Witold Rzyman Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
description	New drugs, including immune checkpoint inhibitors and targeted therapy, have changed the prognosis in a subset of patients with advanced lung cancer, and are now actively investigated in a number of trials with neoadjuvant and adjuvant regimens. However, no phase III randomized studies were published yet. The current narrative review proves that targeted therapies are safe in neoadjuvant approach. Unsurprisingly, administration of therapy is related to an acceptable toxicity profile. Severe adverse events’ rate that rarely compromises outcomes of patients with advanced lung cancer is not that commonly accepted in early lung cancer as it may lead to missing the chance of curative surgery. Among those complications, the most important factors that may limit the use of targeted therapies are severe respiratory adverse events precluding the resection occurring after treatment with some anaplastic lymphoma kinase and rarely after epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in the presented literature assessing the feasibility of neoadjuvant therapies with anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase inhibitors, we did not find any unexpected intraoperative events that would be of special interest to a thoracic surgeon. Moreover, the postoperative course was associated with typical rate of complications.
format	article
author	Tomasz Marjanski Robert Dziedzic Anna Kowalczyk Witold Rzyman
author_facet	Tomasz Marjanski Robert Dziedzic Anna Kowalczyk Witold Rzyman
author_sort	Tomasz Marjanski
title	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
title_short	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
title_full	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
title_fullStr	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
title_full_unstemmed	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
title_sort	safety of surgery after neoadjuvant targeted therapies in non-small cell lung cancer: a narrative review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c374715028cc4681a3df8270fb6f11ae
work_keys_str_mv	AT tomaszmarjanski safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview AT robertdziedzic safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview AT annakowalczyk safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview AT witoldrzyman safetyofsurgeryafterneoadjuvanttargetedtherapiesinnonsmallcelllungcanceranarrativereview
_version_	1718411886191443968

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review

Ejemplares similares